没有标题浙江大学教学信息化平台课件_第1页
没有标题浙江大学教学信息化平台课件_第2页
没有标题浙江大学教学信息化平台课件_第3页
没有标题浙江大学教学信息化平台课件_第4页
没有标题浙江大学教学信息化平台课件_第5页
已阅读5页,还剩43页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

Part4

DrugsforTreatmentofCongestiveHeartFailureContents

OverviewACEinhibitorsDiureticsreceptorblockersCardiacglycosideOthersHeart(cardiac)failureissaidtohaveoccurredwhentheheartisnolongerabletomaintainthecirculationtothetissuesfornormalmetabolism.1.

Pathophysiologicalchangesofcongestiveheartfailure(CHF)(1)Functionandstructurechanges(2)Increasedsympatheticactivityanddown-regulationofreceptor(3)Activatedrenin-angiotensin-aldosteronesystem(RAAS)A.

OverviewPathophysiologicalchangesofCHFPathophysiologicalchangesofCHFCardiacfailureCardiacoutputVenouspressureVenoushyperemiaPulmonarycirculation:cough,emptysis,dyspneaSystemiccirculation

hyperemia

:jugularveindistension,edemaBloodsupplyRenalbloodflowRenin-angiotensionⅡAldosteroneSodiumandwaterretentionChangesinhemodynamicsofCHFA.

Overview2.GradesofCHF

Ⅰ(A):nosymptomsⅡ(B):physicalactivitieswerelimitedandsymptomscouldbeinducedbygeneralactivityⅢ(C):physicalactivitiesweremarkedlylimitedⅣ(D):symptomsappearevenatrest3.TherapeuticstrategiesinCHF(1)Increasingcontractilityofthecardiacmuscles(2)InhibitingRAAS(3)Reducingsympatheticactivity(4)Dilatingvessels(5)Diuresis

A.

Overview

Cardiacremodeling

Decreaseoverload

DrugtherapyforCHFACEI:

captopril卡托普利

enalapril依那普利AT1receptorantagonists:

losartan氯沙坦

irbesartan伊白沙坦B.

Angiotensinconvertingenzymeinhibitors(ACEI)andangiotensinreceptorantagonistsCardiovascularremodelingvasodilatationSystemicandlocalACEI1.PharmacologicaleffectsInhibitingtheproductionofAngIIvasoconstriction

;sodiumretention

;cardiacremodeling(myocardialhypertrophy)

InhibitingthedegradationofbradykininvasodilatationIncreasingANPandscavengingfreeradicals

B.

Angiotensinconvertingenzymeinhibitors(ACEI)andangiotensinreceptorantagonistsBox

ActionsofangiotensinII

throughactivatingAT1receptorsConstrictingvessels,increaseperipheralresistanceandreturnedbloodvolume.Increasingsympathetictension,promotereleaseofsympathetictransmitter.Stimulatingreleaseofaldosterone.Rapidlyinducingexpressionofc-fos,c-jun,Egr-1,c-myc,etc.CardiovasculareffectsDecreaseresistanceofperipheralvesselsDilatecoronaryartery,increasebloodsupplyofheartandkidney,improvecardiacandrenalfunctionReversemyocardialhypertrophyandventricularremodelingB.

Angiotensinconvertingenzymeinhibitors(ACEI)andangiotensinreceptorantagonistsB.

Angiotensinconvertingenzymeinhibitors(ACEI)andangiotensinreceptorantagonists2.Clinicaluses(1)CHFincreasemotortolerancedecreasemortality(2)Hypertension

3.Adverseeffects

HypotensionCoughandangioedemaHyperpotassemia

RashesandalteredtastesContraindications:pregnancyandstenosisofrenalarteryB.

Angiotensinconvertingenzymeinhibitors(ACEI)andangiotensinreceptorantagonistsAT1receptorantagonistsComparedwithACEI:BlockingactionsofangiotensinIIdirectlyNotaffectingbradykininmetabolismProtectingrenalfunctionUsedforCHFandhypertension

B.

Angiotensinconvertingenzymeinhibitors(ACEI)andangiotensinreceptorantagonists1.Pharmacologicaleffects

ReducebloodvolumebyincreasingNa+andwaterexcretionReduceNa+-Ca2+exchangeinvascularsmoothmusclecells2.ClinicalusesCHF:grandI–IV(mainlyusedinII–III),

aloneorcombinedwithotherdrugsEdema,hypertension,etc.3.Adverseeffectsimbalanceofelectrolytes/acid-base;plasmalevelofrenin;hypokalemia;hyperuricemia;hyperglycemia/hyperlipidemiaC.

DiureticsTherapeuticeffectsofdiureticsinCHFMaindiureticsThiazidesLoopdiureticsK+sparingdiuretics类别(主要作用部位)其他分类名作用机制利尿应用非利尿应用碳酸酐酶抑制药(近曲小管)/抑制碳酸酐酶利尿药耐受的病人,与袢利尿药合用青光眼,高山病,代谢性碱中毒渗透性利尿药(髓袢及其他部位)脱水药增高尿液渗透压急性肾功能衰竭脑水肿,青光眼袢利尿药(髓袢升支粗段)1.高效能利尿药2.Na+-K+-2C1—同向转运体抑制药抑制Na+-K+-2C1—同向转运各种严重水肿,急性肾功能衰竭高钙血症,加速毒物排出噻嗪类利尿药(远曲小管)1.中效能利尿药2.Na+-C1—同向转运体抑制药抑制Na+-C1—同向转运各种水肿高血压,高尿钙症,尿崩症保钾利尿药(集合管、末段远曲小管)低效能利尿药1.拮抗醛固酮作用(螺内酯)2.抑制上皮细胞Na+通道(氨苯蝶啶,阿米洛利)水肿(尤其对伴有醛固酮增高者,如肝硬化病人)失钾和/或失镁Commonlyused:carvedilol卡维地洛,bisoprolol比索洛尔,sustained-releasemetoprolol缓释型美托洛尔

1.Pharmacologicaleffects(1)Blockingeffectsofcatecholaminesonmyocardium:decreasingheartrateandcardiacoxygendemand(2)Up-regulatingreceptor(3)InhibitingRAASandVP(vosopressin,加压素):anti-myocardialhypertrophyandremodeling(4)Reducingcardiacoxygenremand,vasodilatation(receptorblock)(5)Anti-arrhythmicandanti-hypertensiveeffects

D.

receptorblockers2.Clinicaluses(1)CHF:grandII-IIIdecreasingmortality(2)Otheruses:

hypertension,arrhythmias,angina,etc.D.

receptorblockersTherapeuticeffectsof

receptorantagonistsoncardiacfunctioninCHFpatientsD.

receptorblockers3.AdverseeffectsInhibitionofcardiacfunctionContraindications:

severeheartfailuresevereA-VblockhypotensionworseningbronchialasthmaD.

receptorblockersE.

Cardiacglycoside

(digitalis)Cardiacglycoside

:Itisakindofglycosidecompoundswhichcanselectivelyactoncardiacmuscle,andincreasetheforceofmyocardialcontraction.

Digoxin地高辛E.

Cardiacglycoside

(digitalis)1.Pharmacologicaleffects(1)Positiveinotropiceffects

inhibitingNa+-K+-ATPase

freeCa2+

excitation-contractioncoupling

cardiacoutput

organbloodsupply

Vmax

diastolicduration

venousreturn

coronarybloodsupply

cardiacoxygenconsumptionE.

Cardiacglycoside

(digitalis)InhibitionofNa+-K+-ATPasebydigitalisandpotentiationofcardiacmusclecontraction(2)Negativechronotropiceffects

Reflexinhibitionofsympatheticactivity

cardiacoutput

Sympatheticactivity

HRIncreasingvagalactivity

directly

ReducingAVconduction:ventricularrate

E.

Cardiacglycoside

(digitalis)(3)Electrophysiologicaleffects

decreasingautomaticityofsinoatrialnode

slowconduction,especiallyAVconduction

increasingautomaticityofPurkinjefibresshorteningERPoffastresponsecellsMechanisms:intracellularNa+

,K+

,Ca2+

MDP,afterdepolarization

E.

Cardiacglycoside

(digitalis)Overdose:Na+

,K+

,Ca2+

MDP

afterdepolarizationElectrophysiologicalbasisfordigitalisoverdoseECG:

P-R;S-T/Twave;variousarrhythmiasP-RS-T/Twave

prematuralventricularbeat(4)OthereffectsVessels:vasoconstriction

Centralnervoussystem:

CTZdopamineD2receptormentalandvisiondisordersKidneyincreasebloodsupplyofkidneydiureticeffect:decreaseNa+reabsorption

E.

Cardiacglycoside

(digitalis)2.Clinicaluses(1)Congestiveheartfailure(CHF)

especiallyassociatedwithatrialfibrillationandsinustachycardia(2)Arrhythmias

atrialfibrillation/atrialflutter:

paroxysmalsurpraventriculartachycardia

E.

Cardiacglycoside

(digitalis)3.Adverseeffects(1)Gastrointestinaleffectsnausea,vomiting,etc.(2)CNSeffectsalterationofcolorperception〔色视,suchasyellowvision黄视〕;headache,fatigue,confusion,etc.E.

Cardiacglycoside

(digitalis)(3)Cardiactoxicity

arrhythmias:prematuralbeats,

tachycardia,atrioventricularblock,sinusbradycardia,etc.Prevention:DoseindividualizationAvoidingprovocationfactors:plasmaK+

,anddruginteractions,etc.Treatment:

KCl,phenytoinorlidocaine,i.v.

Atropine:A-Vblock,sinusbradycardia

Fabsegmentofdigoxinantibody,i.v.E.

Cardiacglycoside

(digitalis)Druginteractionsthatprobablyinducedigitaliscardiotoxicity4.Administration(1)Loading+maintainingdosesfulldose(digitalization)+maintainingdosesforseverepatients(2)Maintainingdose

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论